Issue 11, 2013
From the journal:

Organic & Biomolecular Chemistry

The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib

Benjamin J. Deadman,a   Mark D. Hopkin,a   Ian R. Baxendaleb  and  Steven V. Ley*a  

* Corresponding authors

a Innovative Technology Centre, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, UK
E-mail: svl1000@cam.ac.uk

b Department of Chemistry, Durham University, South Road, Durham, UK
E-mail: i.r.baxendale@durham.ac.uk

Abstract

Imatinib (1), nilotinib (2) and dasatinib (3) are Bcr-Abl tyrosine kinase inhibitors approved for the treatment of chronic myelogenous leukemia (CML). This review collates information from the journal and patent literature to provide a comprehensive reference source of the different synthetic methods used to prepare the aforementioned active pharmaceutical ingredients (API's).

Graphical abstract: The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib

About
Cited by
Related
Download options Please wait...

Article information

DOI
https://doi.org/10.1039/C2OB27003J
Article type
Perspective
Submitted
15 Oct 2012
Accepted
04 Dec 2012
First published
05 Dec 2012

Org. Biomol. Chem., 2013,11, 1766-1800

Permissions

Request permissions

The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib

B. J. Deadman, M. D. Hopkin, I. R. Baxendale and S. V. Ley, Org. Biomol. Chem., 2013, 11, 1766 DOI: 10.1039/C2OB27003J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements